Lexaria's Hormone Study Shows Significant Enhancement In Oral Estradiol Delivery
Portfolio Pulse from Happy Mohamed
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) announces successful completion of its animal study HOR-A22-1, showing significant enhancement in oral delivery of estrogen hormone estradiol using DehydraTECH. The hormone replacement market is estimated at $46.5 billion in 2027.
May 18, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH shows significant enhancement in oral estradiol delivery, potentially improving safety and efficacy in human hormone therapies.
The successful completion of the animal study indicates that DehydraTECH has the potential to improve the oral delivery of estradiol, which is an important component of therapeutic products in the women's health sector. This could lead to increased demand for Lexaria's technology and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Lexaria Bioscience's DehydraTECH shows significant enhancement in oral estradiol delivery, potentially improving safety and efficacy in human hormone therapies.
The successful completion of the animal study indicates that DehydraTECH has the potential to improve the oral delivery of estradiol, which is an important component of therapeutic products in the women's health sector. This could lead to increased demand for Lexaria's technology and positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100